<DOC>
	<DOCNO>NCT02040636</DOCNO>
	<brief_summary>Primary objective : - To determine safety immunogenicity tetanus diphtheria toxoid adsorb combined component pertussis inactivate poliomyelitis vaccine grow vero cell ( TdcP-IPV ) compare tetanus diphtheria toxoid adsorb combined component pertussis inactivate poliomyelitis vaccine grow vero cell ( TdcP-IPV ) Hepatitis B vaccine administer concurrently adolescents 11-14 year age . Secondary objective : - To determine whether concurrent administration TdcP-IPV Hepatitis B vaccines 11-14 year age result detectable immunologic interaction component two vaccine .</brief_summary>
	<brief_title>Study Tetanus Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine Inactivated Poliomyelitis</brief_title>
	<detailed_description>Participants randomize one 2 group receive either dose TdcP-IPV Day 0 ( visit 1 ) Hepatitis B vaccine subsequent visit 2 , 3 4 ( Group 1 ) ; vaccination Day 0 , concomitant administration TdcP-IPV Hepatitis B vaccine Day 28 ( Visit 2 ) Hepatitis B vaccine subsequent visit 3 4 ( Group 2 ) . All participant follow immunogenicity safety</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 11 year &lt; 14 year age . Signed , witness date informed consent obtain prior first study intervention . Judged good health basis report medical history . Plans remain study area length trial . All minor parent legal guardian read , write understand English French . Pregnancy test perform female participant time enrollment study ( prior day first immunization visit ) . Pregnancy . Known suspect primary disease immune system [ condition suspect immunologic component autoimmune disease ( rheumatoid arthritis inflammatory bowel disease ) exclude unless meet exclusion criterion 3 sufficiently clinically active meet exclusion criterion 5 ] . Malignancy receive immunosuppressive therapy ( e.g. , daily systemic prednisone â‰¥ 1 mg/kg would exclude , participant take topical inhaled steroid could include study could participants `` short course '' oral steroid , 57 day , long two course within previous two week period ) . Prior receipt pertussis , diphtheria , tetanus polio contain vaccine , include Hepatitis B vaccine , within past 5 year . Any significant underlying chronic disease , include malignancy , cardiopulmonary disease , renal hepatic dysfunction . Known impairment neurologic function seizure disorder etiology . Personal history physician diagnose laboratory confirm pertussis disease within last 2 year . Receipt blood product immunoglobulin within previous 3 month . Known suspect allergy vaccine intend use study vaccine component include neomycin , streptomycin polymyxin B . Receipt vaccine within 2 week receive study vaccine . Daily use nonsteroidal antiinflammatory drug .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Acellular Pertussis Vaccines</keyword>
</DOC>